| |
| Issue |
Title |
| |
| No 10 (2024) |
The evolution of treatment for advanced cervical cancer: from cisplatin monotherapy to immuno-oncology combinations |
Abstract
PDF (Rus)
|
|
A. A. Rumyantsev, A. N. Letuchikh |
| |
| No 11 (2023) |
Discussion article: do we understand the role of local treatments after oligoprogression of ovarian cancer on PARP inhibitors? |
Abstract
PDF (Rus)
|
|
A. A. Rumyantsev, A. K. Zarenkova, V. Yu. Kirsanov |
| |
| No 9 (2022) |
Olaparib maintenance therapy after frontline chemotherapy in patients with BRCA-mutated ovarian cancer: real-world results in expanded access program |
Abstract
PDF (Rus)
|
|
A. A. Rumyantsev, A. S. Tyulyandina, I. A. Pokataev, E. R. Israelyan, M. Е. Abramov, H. N. Lud, S. A. Tyulyandin |
| |
| No 20 (2021) |
Lenvatinib and pembrolizumab in the treatment of metastatic endometrial cancer: literature review and case report |
Abstract
PDF (Rus)
|
|
A. A. Rumyantsev |
| |
| No 9 (2021) |
The role of immunotherapy in the management of metastatic/recurrent female reproductive system neoplasms |
Abstract
PDF (Rus)
|
|
A. A. Rumyantsev, A. Yu. Anokhin |
| |
| No 20 (2020) |
The latest first-line treatment options for ovarian cancer: focus on maintenance therapy |
Abstract
PDF (Rus)
|
|
A. A. Rumyantsev |
| |
| No 9 (2020) |
Molecular-guided therapy for disseminated cervical cancer: present and future |
Abstract
PDF (Rus)
|
|
A. А. Rumyantsev |
| |
| No 9 (2020) |
Is it possible to improve primary therapy of advanced ovarian cancer? |
Abstract
PDF (Rus)
|
|
S. V. Khokhlova |
| |
| 1 - 8 of 8 Items |
|
